Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CHO PharmaROCO:6586 -3.83%31 EV-to-EBITDA is -80.15 as of Sep. 04, 2026. GuruFocus rates ROCO:6586 with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 403 Biotechnology companies, CHO Pharma ranks worse than 248138.71% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CHO Pharma's enterprise value is NT$19,555.13 Mil.
CHO Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-243.98 Mil. Therefore, CHO Pharma's EV-to-EBITDA for today is -80.15.
The historical rank and industry rank for CHO Pharma's EV-to-EBITDA or its related term are showing as below:
ROCO:6586'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -254.35 Med: -31.86 Max: -2.86
Current: -80.15
During the past 13 years, the highest EV-to-EBITDA of CHO Pharma was -2.86. The lowest was -254.35. And the median was -31.86.
ROCO:6586's EV-to-EBITDA is ranked worse than 100% of 403
companies
in the Biotechnology industry
Industry Median: 13.7
vs ROCO:6586: -80.15
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CHO Pharma's share price for today is NT$100.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CHO Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-1.260.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for CHO Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6586 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, CHO Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CHO Pharma EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CHO Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CHO Pharma's EV-to-EBITDA falls into.
CHO Pharma's current Enterprise Value is NT$19,555.13 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CHO Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-243.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHO Pharma (ROCO:6586) has a EV-to-EBITDA of -80.15 as of Sep. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CHO Pharma. According to the industry distribution chart, CHO Pharma ranks #999999 out of 403 companies in the Biotechnology industry.
Is CHO Pharma's EV-to-EBITDA too high?
CHO Pharma's current EV-to-EBITDA is -80.15. Based on the distribution chart, CHO Pharma ranks #999999 out of 403 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CHO Pharma has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does CHO Pharma's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CHO Pharma ranks #999999 out of 403 companies for EV-to-EBITDA. This places CHO Pharma in the lower half of its industry. The industry median EV-to-EBITDA is 13.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.70, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CHO Pharma. For the Biotechnology industry, the median EV-to-EBITDA is 13.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CHO Pharma's current EV-to-EBITDA is -80.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CHO Pharma stock overvalued right now?
CHO Pharma (ROCO:6586) has a current EV-to-EBITDA of -80.15. The current EV-to-EBITDA is -80.15. CHO Pharma's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For CHO Pharma (ROCO:6586), the current EV-to-EBITDA is -80.15 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.
31GF Score
Get the complete analysis for ROCO:6586
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6586 has been successfully added to your 
